Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/3044% above fair value
$0.53+0.00 (+0.21%)
Close on Nov 13, 2026Market cap $73.36MP/E –Yield –
Rani Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Rani Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -530.5%. For fiscal 2025 it was -2346.0%, against -5186.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2346.0% | +2840.2 |
| FY2024 | Dec 31, 2024 | -5186.2% | −3287.1 |
| FY2021 | Dec 31, 2021 | -1899.1% | +1681.8 |
| FY2020 | Dec 31, 2020 | -3581.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -540.3% | +6444.0 |
| Q2 FY2026 | Jun 30, 2026 | -516.9% | +938.2 |
| Q1 FY2026 | Mar 31, 2026 | -488.2% | −220.1 |
| Q4 FY2025 | Dec 31, 2025 | -584.2% | +103.4 |
| Q1 FY2025 | Mar 31, 2025 | -6984.3% | −4630.0 |
| Q4 FY2024 | Dec 31, 2024 | -1455.1% | +1162.5 |
| Q2 FY2021 | Jun 30, 2021 | -268.1% | +5381.9 |
| Q1 FY2021 | Mar 31, 2021 | -687.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -2354.3% | – |
| Q3 FY2020 | Sep 30, 2020 | -2617.6% | – |
| Q2 FY2020 | Jun 30, 2020 | -5650.0% | – |
See a number that looks wrong?